Serum NfL and GFAP levels and their association with anxiety-depression in Alzheimer’s disease patients: A clinical retrospective study

Table 5 Sensitivity analysis and subgroup analysis

Analysis type	Subgroup	AUC (95%CI)	Sensitivity/specificity
Primary analysis	Overall (n = 270)	0.882 (0.836-0.928)	81.1%/84.5%
Stricter criteria	HADS ≥ 10	0.868 (0.818-0.918)	79.6%/83.2%
Gender-stratified	Male (n = 125)	0.876 (0.814-0.938)	80.0%/84.3%
Gender-stratified	Female (n = 145)	0.886 (0.834-0.938)	82.1%/84.7%
Cognitive severity	Moderate (MMSE 10-18)	0.902 (0.858-0.946)	83.8%/86.2%
Cognitive severity	Mild (MMSE 19-26)	0.848 (0.786-0.910)	77.4%/81.9%
Education-stratified	Low education (≤ 9 years)	0.874 (0.822-0.926)	79.8%/83.6%
Education-stratified	High education (> 9 years)	0.888 (0.836-0.940)	82.4%/85.2%
Disease duration	Early stage (≤ 3 years)	0.876 (0.820-0.932)	80.3%/83.8%
Disease duration	Later stage (> 3 years)	0.890 (0.832-0.948)	81.9%/85.1%

AUC: Area under curve; CI: Confidence interval; HADS: Hospital Anxiety and Depression Scale; MMSE: Mini-Mental State Examination.